Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn’s Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00102921
Recruitment Status : Completed
First Posted : February 7, 2005
Last Update Posted : March 14, 2006
Information provided by:

February 4, 2005
February 7, 2005
March 14, 2006
August 2004
Not Provided
  • Crohn’s Disease Activity Index score
  • Safety (Adverse Events, tolerability)
Same as current
Complete list of historical versions of study NCT00102921 on Archive Site
  • Inflammatory Bowel Disease Questionnaire
  • C-reactive protein
  • Endoscopic appearance and biopsy of colon and terminal ileum
  • Markers of leukocyte subsets and activation status
Same as current
Not Provided
Not Provided
Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn’s Disease
Pilot, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety Clinical Activity of CCX282-B in Patients With Moderate to Severe Crohn’s Disease
The purpose of this research study is to investigate the effects of an investigational medication, called CCX282-B, on safety and on the some of the symptoms of Crohn’s Disease in patients who are experiencing an active flare-up of moderate to severe Crohn’s Disease.

CCX282-B is being developed as a treatment for inflammatory bowel diseases such as Crohn’s Disease. CCX282-B is a highly potent, orally active, chemokine receptor antagonist whose single target is the G-protein coupled receptor CCR9. The CCR9 receptor is expressed by most T-cells in the thymus as well as in the intestine, and by a small population of T-cells in the peripheral blood. In humans, the CCR9 receptor is implicated in Crohn’s Disease and ulcerative colitis.

Crohn’s Disease is an autoimmune disease involving the entire length of the gastrointestinal tract, but with most manifestations in the terminal small intestine and colon. This condition is characterized by mucosal ulcerations that penetrate deeply into the bowel wall. Sometimes the ulcerative lesions completely penetrate the bowel wall, leading to fistula formation and infectious complications requiring surgical intervention. Patients experience considerable lifestyle disruption and disability from this disease, including diarrhea, abdominal pain, malnutrition, anemia, and repetitive surgeries to remove disease-affected gastrointestinal segments.

ChemoCentryx Protocol CL003_282 is a double-blind, placebo-controlled, parallel group, two stratum, Phase 2A pilot study of the safety, tolerability, immunologic and clinical activity, and population pharmacokinetics of a single dose level of CCX282-B administered daily for four consecutive weeks to patients with active, moderate to severe Crohn’s Disease. The primary immunologic and clinical activity objective of this study is to provide pilot information regarding the immunologic and clinical activity of daily oral doses of CCX282-B in the treatment of moderate to severe Crohn’s Disease, based on changes in the Crohn’s Disease Activity Index (CDAI). Secondary immunologic and clinical activity objectives include evaluation of the effect of CCX282-B on the Inflammatory Bowel Disease Questionnaire (IBDQ) instrument, C-reactive protein (CRP), the endoscopic appearance and biopsy of the colon and terminal ileum, and markers of leukocyte subsets and activation status. The primary safety objective of this study is to evaluate the safety and tolerability of oral doses of CCX282-B in patients with moderate to severe Crohn’s Disease. In addition, blood samples will be collected for evaluation of the population pharmacokinetics of CCX282-B.

Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Crohn Disease
Drug: CCX282-B
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
December 2005
Not Provided

Inclusion Criteria:

  • Diagnosis of moderate to severe Crohn's Disease in small intestine; disease must be active at the time of study entry
  • Use of adequate and approved methods of birth control throughout the study period
  • Willing and able to sign an informed consent

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV; the virus that causes AIDS)
  • Abuse of alcohol or of illegal drugs
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Study Director: JJ Kim Wright, PhD ChemoCentryx, Inc
March 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP